Center for Addictive Disorders

BioMe® Biobank

The Charles Bronfman Institute for Personalized Medicine brings together a group of experts in the clinical and biological data sciences committed to exploring the nature of human disease through cohort studies. We carry out these studies at scale in clinics, emergency rooms, and inpatient units within the Mount Sinai Health System.

The institute collaboratively and rapidly translates key discoveries into experimental interventions and new standards of care. We aim to position Mount Sinai at the forefront of data-driven clinical care by creating a landscape where every patient can be a research participant, clinical decisions are data-driven, and care is continuously optimized.

Mount Sinai Million Health Discoveries Program

Institute leadership has special experience in designing and executing challenging, high-impact cohort studies embedded into the daily flow of clinical care. Building on this experience, we are launching the Mount Sinai Million Health Discoveries Program, a real-world genetic cohort study of one million Mount Sinai patients.

This study will yield fundamental discoveries that our researchers will be able to translate into experimental interventions and new treatment guidelines. Our goal is to develop standards of rigor for incorporating predictive models into clinical care.

To enroll as a participant or to learn more about the Mount Sinai Million Health Discoveries Program, visit mountsinaimillion.org.

In the News

Apr 04, 2022

Oxford-Mount Sinai Consortium on Bioethics

In the spring of 1992 faculty representatives from Mount Sinai School of Medicine and its affiliates, Oxford University, and The Graduate School, CUNY, joined to form the Oxford-Mount Sinai Consortium on Bioethics. Since then, the group has evolved. The participating institutions now include: Icahn School of Medicine at Mount Sinai, Oxford University, King's College London, the Vrije University of Amsterdam, and Bar Ilan University and the participating faculty members have become a community of scholars.

Mar 31, 2022

Team at BioMe Is Hailed as ‘Warm and Knowledgeable’

Amanda Merkelson, MPH, Associate Director of the BioMe Biobank Program, is proud of her team that has been instrumental in enrolling a diverse population of patients in the vital pursuit of genomic studies.

Mar 31, 2022

ImmuneID Announces Key Partnerships with Icahn School of Medicine at Mount Sinai and University Hospital Erlangen to Advance Novel Immune System Insights

Partners to Provide Unique Expertise and Resources into Immune System Exposure, Patient Segmentation, and Target Identification

Jan 26, 2022

Clinical Characterization of Copy Number Variants Associated With Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank

To identify individuals harboring NDD CNVs in a multiancestry biobank and to query their enrichment for select neuropsychiatric disorders as well as association with multiple medical disorders.

Jan 25, 2022

Population-Based Penetrance of Deleterious Clinical Variants

Population-based assessment of disease risk associated with gene variants informs clinical decisions and risk stratification approaches.

Oct 21, 2021

Mount Sinai Leader Awarded 2021 Sherman Prize for Advancements in Understanding IBD Genetics

The Bruce and Cynthia Sherman Charitable Foundation has announced Judy H. Cho, MD as a recipient of the 2021 Sherman Prize, which recognizes excellence in the field of Crohn’s disease and ulcerative colitis, two forms of inflammatory bowel disease (IBD).

Jun 07, 2021

New Division of Data Driven and Digital Medicine Within the Department of Medicine

We are pleased to announce the establishment of a new Division of Data Driven and Digital Medicine within the Department of Medicine at the Icahn School of Medicine at Mount Sinai. Led by Girish N. Nadkarni, MD, the Division’s mission is to create a data science and digital health hub to catalyze translational research.

Jun 05, 2021

Non-Invasive Ventilation Versus Mechanical Ventilation in Hypoxemic Patients with COVID-19

Forrest IS, Jaladanki SK, Paranjpe I, Glicksberg BS, Nadkarni GN, Do R. Infection. 2021 Jun 5:1-9. doi: 10.1007/s15010-021-01633-6. Online ahead of print. PMID: 34089483

May 19, 2021

How COVID-19 Long-Haulers Can Get Back to Physical Activity

As part of our COVID-19 Long-Hauler study, this shows COVID-related symptoms weighted by the number of BioMe participants for whom those symptoms were still being discussed 90 days following COVID-19 diagnosis, when never mentioned for those participants prior to two weeks before diagnosis, so as to ignore preexisting symptoms. While we have data on 2604 Covid+ patients in BioMe, this represents 681 participants who had notes available 90 days post-diagnosis." -Tielman Van Vleck, IPM Associate Computational Scientist and BioMe Co-Investigator

Apr 01, 2021

Understanding Acute Kidney Injury as a Complication of COVID-19

Lili Chan & Girish N Nadkarni #nephrology #covid19 #NadkarniLab #MountSinaiCOVIDInformaticsCenter

Mar 31, 2021

A Myeloid–Stromal Niche and GP130 Rescue in NOD2-driven Crohn’s Disease

New study identifies a new approach that will help personalize treatment for patients diagnosed with Crohn’s disease. #judycho #chrohns

Mar 15, 2021

Sanford J. Grossman Charitable Trust Pledges $5.9 Million to Establish Interdisciplinary Center in Neural Circuitry and Immune Function at Mount Sinai

The Sanford J. Grossman Charitable Trust, founded by renowned economist and philanthropist Sanford J. Grossman, PhD, has committed $5.9 million to establish the Sanford Grossman Interdisciplinary Center in Neural Circuitry and Immune Function at the Icahn School of Medicine at Mount Sinai.

Feb 01, 2021

Effect of Sickle Cell Trait and APOL1 Genotype on the Association of Soluble uPAR with Kidney Function Measures in Black Americans

Soluble urokinase plasminogen activator receptor (suPAR) is the circulating form of urokinase plasminogen activator receptor, a glycosyl-phosphatidylinositol–anchored membrane protein expressed in various cell types including kidney podocytes and endothelial cells.

Jan 29, 2021

Major Grant Enables Top Researcher to Put Down Roots in Denmark

IPM researcher Professor Ruth Loos was offered the opportunity to join the NNF Center for Basic Metabolic Research and awarded seven-year DKK50 million Laureate Research Grant from the Novo Nordisk Foundation.

Jan 27, 2021

Integrated Spatial Genomics Reveals Global Architecture of Single Nuclei

Identifying the relationships between chromosome structures, nuclear bodies, chromatin states and gene expression is an overarching goal of nuclear-organization studies.

Dec 04, 2020

Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months

BioMe called “heroes” for providing 360 de-identified plasma samples to Mount Sinai’s Department of Pathology, Molecular and Cell-based Medicine to help “define the normal level of Cytokines and anti COVID19 Antibodies required by the NYSDOH Wadsworth Center.”

Nov 23, 2020

Discovery of Rare Variants Associated with Blood Pressure Regulation Through Meta-analysis of 1.3 Million Individuals

Genetic studies of blood pressure (BP) to date have mainly analyzed common variants (minor allele frequency > 0.05).

Oct 23, 2020

Autoantibodies Against Type I IFNs in Patients with Life-Threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast.

Oct 19, 2020

BioMe Principal Investigator Elected to the National Academy of Medicine

The National Academy of Medicine (NAM) is a leading organization dedicated to promoting science, health equity, and trusted medical advice nationally and globally in order to broadly promote human health. For these reasons, I am deeply honored to have been elected to NAM. This recognition substantially reflects the impact of BioMe as a forward-looking research endeavor committed to rapidly applying research advances to improve patient health. On a personal level, I am a participant in BioMe; by volunteering, each of us can advance knowledge to improve outcomes for ourselves and others.

Jun 15, 2020

Human CRY1 Variants Associate with Attention Deficit/Hyperactivity Disorder

Recent study published in the JCI, the Itan lab demonstrated a good use of BioMe Biobank samples where they performed PheWAS analyses in BioMe Biobank samples to support the evidence that mutations in the gene CRY1 are associated with ADHD and insomnia

Jun 09, 2020

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

Polygenic risk scores (PRS) for coronary artery disease (CAD) identify high-risk individuals more likely to benefit from primary prevention statin therapy.